Natural product-derived therapy for glucose homeostasis and TIIDM: Celastrol, isolated from herb Thunder God Vine, inhibits Amysin expression, increases insulin secretion, and decreases the risk of hyperglycemia via down regulation of its target gene Sox4, 25/February/2017, 11.17 pm
Introduction: What they say Nobel laureate in Physiology/Medicine (1975) Prof. David Baltimore and his research team, from California Institute of Technology, California, USA, had reported in the September 14, 2014 issue of the Journal “Journal of Experimental Medicine (JEM)” that: “The microRNA-212/132 cluster regulates B cell development by targeting Sox4.” Subsequently, Prof. Rorsman’s research team, […]
Natural product-derived therapy for Human Leukemias: Lutein, one of the main components of Marygold, suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4, 25/February/2017, 10.51 pm
Introduction: What they say Noble laureate in Physiology/Medicine (1975) Prof. David Baltimore, from California Institute of Technology, California, USA, had reported in the July 8, 2014 issue of the Journal “Blood” that: “Dual mechanisms by which MiR-125b represses IRF4 to induce myeloid/B-cell leukemias.” What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-derived therapy for Human Leukemias: Lutein, […]
Anti-telomerase cancer therapy: MAG13 (Membrane Associated Guanylate Kinase Inverted 3) suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and the cellular immortality gene telomerase and inhibits cancer progression via down-regulation of it target gene, 25/February/2017, 10.34 pm
Introduction: What they say: The 1989 Nobel prize winner in Chemistry, Prof. Thomas R. Cech from the BioFrontiers Institute, USA has published a research paper in the 13 December 2012 issue of the Nature journal (492(7428):285-9; and I.F: >42) stating that “The TEL patch of telomere protein TPP1 mediates telomerase recruitment and processivity.” This study provides mechanistic insights into how TPP1 regulates telomerase function. What we say: In connection with this finding, Dr Boominathan, Founder […]
Natural product/vitamin-based Combination therapy for PTEN-deficient cancer: Combination of Schisandrin B, Cholecalciferol and ATRA decreases the expression of CHD1, increases the expression of a number of tumor suppressor genes, inhibits pro-survival TNF-NF-kB gene network, and suppresses tumorigenesis of PTEN-deficient cancer, 24/February/2017, 11.43 pm
Introduction: What they say: A study from the Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA shows that “Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer.” This study was published in the 6 February 2017 issue of the journal “Nature” [the number 1 journal in […]
Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy: Bergapten, isolated from Bergamot, inhibits the expression of PD-L1, inhibits inflammatory signalling and the number of tumor-infiltrating lymphocytes and macrophages, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 24/February/2017, 11.27 pm
Introduction:What they say: A recent study from Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030, USA shows that “Deubiquitination and Stabilization of PD-L1 by CSN5.” This study was published in the 12 December 2016 issue of Cancer cell (one of the best journals in […]
Combination therapy for augmenting the anti-cancer drug 5-FU (5-Flurouracil) sensitivity in Human cancers: 15-deoxy-delta(12,14)-prostaglandin J2 (PGJ2) decreases the expression of the rate-limiting enzyme of the ‘uracil catabolic pathway’ Dihydropyrimidine dehydrogenase (DPYD), increases 5-FU accumulation in cancer cells, augments chemosensitivity, and anti-tumor effect via upregulation of its target gene, 24/January/2017, 11.01 pm
From Research findings to Therapeutic opportunity: The study presented here suggests that 15-deoxy-delta(12,14)-prostaglandin J2 (PGJ2), by increasing the expression of its target genes, it may: (i) decrease the expression of Dihydropyrimidine dehydrogenase (DPYD); (ii) increase 5-FU accumulation in cancer cells; (iii) augment and restore chemosensitivity in drug-resistant Human cancers; (iv) promote anti-tumor effect; and (v) enhance the efficacy of anticancer […]